9 results about "Eosinophilic esophagitis" patented technology

The present invention relates to an antisense oligonucleotide targeting an interleukin 4 receptor and the use thereof. The antisense oligonucleotide (ASO) molecule has a length of 16-22 bases and is specifically paired with a specific region of a target gene (interleukin 4 receptor). The ASO is used for treating diseases associated with IL-4Rα, which includes, but is not limited to, asthma (including eosinophilic asthma), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, prurigo nodularis, urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, pruritus, and gastritis.

TSLP-TRAPs are a novel class of biologics that have been developed to inhibit the activity of TSLP. By binding to TSLP, TSLP-TRAPS effectively block the interaction between TSLP and its receptor, preventing downstream signaling and immune cell activation. This makes TSLP-TRAPs an attractive therapeutic option for a variety of inflammatory and allergic diseases, including asthma, atopic dermatitis, and eosinophilic esophagitis.

This invention relates to an antisense oligonucleotide targeting the interleukin-4 receptor and its applications. The antisense oligonucleotide (ASO) molecule is 16-22 bases in length and specifically pairs with a specific region of the target gene (interleukin-4 receptor). The ASO is used to treat diseases related to IL-4Rα, including but not limited to asthma (including eosinophilic types), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, nodular prurigo, urticaria, COPD, bullous pemphigoid, pruritus, and gastritis.

The present invention relates to a water-soluble film containing mometasone furoate, adjusted to a pH in the range of 3.5 to 5.0. Adjusting the pH improves the stability of the active ingredient without significantly affecting the mechanical properties of the film. The present invention further relates to methods for producing such films, pharmaceutical dosage forms containing such films in a capsule, and methods for producing such pharmaceutical dosage forms. The pharmaceutical dosage form can be used, in particular, for the treatment of eosinophilic esophagitis.

The present invention relates to a water-soluble film having a mometasone furoate content adjusted to a pH in the range of 3.5 to 5.0. The correspondingly adjusted pH increases the stability of the active ingredient without substantially impairing the mechanical properties of the film. The present invention further relates to methods for producing such films, pharmaceutical dosage forms containing films of the above type in a capsule, and methods for producing such pharmaceutical dosage forms. The pharmaceutical dosage form can especially be used for treating eosinophilic esophagitis.

Disclosed are methods of diagnosing and treating a subject with active or inactive eosinophilic esophagitis (EoE). The methods may include the steps of detecting whether a level of one or more immunoglobulin antibodies is elevated in an esophageal secretion sample obtained from a subject, diagnosing the subject with active EoE when the level of one or more immunoglobulin antibodies in the sample is elevated above a pre-determined cut-off value and diagnosing the subject with inactive EoE when the level of one or more immunoglobulin antibodies level in the sample is below a pre-determined cut-off value; and treating the subject diagnosed with active EoE.

Aspects of the present application provide bispecific antibodies and methods for using the same to promote barrier function and reduce inflammation and to treat conditions such as Netherton syndrome, eosinophilic esophagitis, and atopic dermatitis. In some embodiments, the bispecific antibodies comprise at least one antigen-specific binding site that specifically binds to KLK5 and KLK7 and at least one antigen-specific binding site that specifically binds to IL-13 or a receptor thereof.

Aspects of the application provide bispecific antibodies and methods for using the same to promote barrier function and reduce inflammation and to treat conditions such as Netherton syndrome, eosinophilic esophagitis, and atopic dermatitis. In some embodiments, the bispecific antibodies comprise at least one antigen-specific binding site that specifically binds to KLK5 and KLK7 and at least one antigen-specific binding site that specifically binds to a Th2 cytokine (e.g., IL-13) or a receptor thereof.

The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) inhibitor such as an anti-IL-4Rα antibody.